Future Gene therapy

Future Reception 2019.07.23

Speeches

Lecturer Profiles

Gene therapy technology innovation and clinical trials are booming in recent years, and a number of gene therapy projects have been approved in the United States, the European Union and other countries. The target of gene therapy has gradually expanded from single gene inherited diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Gene therapy may be the most complex "drug" developed by human beings. Although the research of gene therapy has made remarkable progress, the high cost of development and application, as well as the safety, ethics and regulatory issues involved, are worthy of further study on the development path of its application. In the future, can gene therapy realize people's high hopes of curing major diseases?
In the session, we will invite representatives of scientific research, clinical medicine, pharmaceutical enterprises and medical investment to discuss the cutting-edge progress of gene therapy research, analyze the optimal path of clinical transformation, understand the expectation of market and investment circles, and explore a channel conducive to the development of gene therapy and clinical application.

Moderator

Zilong QIU, Institute of Neuroscience, Chinese Academy of Science, Member of Future Forum YOSIA

Keynote Speech

-Zilong QIU, Institute of Neuroscience, Chinese Academy of Science, Member of Future Forum YOSIA
-Yuxuan WU, Professor, School of Life Sciences, East China Normal University
-Yujia CAI, Researcher of Shanghai Jiaotong University and Co-Founder of BDgene Technology Co., Ltd.
- Xuan YAO, CEO of HuiGene Therapeutics Co., Ltd (Shanghai)
-Chunyi HOU, Director of KPMG China Life Science Industry

Participants

Please fill in the form below

Your Name*

Email*

Tel*

Major*

Leaving a message

Submit

Summary